Eli Lilly (LLY) finance chief granted stock and RSU awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.
He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Zakrowski Donald A
Role
SVP, Finance, & CAO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 199.472 | $0.00 | -- |
| Grant/Award | Common Stock | 583.784 | $1,044.67 | $610K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 199.472 shares (Direct);
Common Stock — 3,423.443 shares (Direct);
Common Stock — 1,728.57 shares (Indirect, 401(k))
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Eli Lilly (LLY) SVP Donald Zakrowski report?
Donald A. Zakrowski reported equity awards from Eli Lilly. On February 9, 2026, he acquired 583.784 shares of common stock as a grant or award and 199.472 restricted stock units, increasing his directly held common stock to 3,423.443 shares.
What price was used for Donald Zakrowski’s Eli Lilly (LLY) stock grant?
The common stock grant to Donald A. Zakrowski was recorded at a price of $1,044.67 per share for 583.784 shares. This reflects the valuation of the grant on February 9, 2026, as disclosed in the Form 4 insider transaction report.
What are the terms of Donald Zakrowski’s Eli Lilly (LLY) restricted stock units?
Donald A. Zakrowski received 199.472 restricted stock units, each representing a contingent right to one share of Eli Lilly common stock. These units have both exercisable and expiration dates of February 16, 2029, and are held directly with a reported price of $0 per unit.